title: The effect of glutamine on locomotor performance and skeletal muscle myosins following spinal cord injury in rats.
abstract: Following initial spinal cord injury (SCI), a cascade of pathological events, including oxidative stress, leads to secondary injury. Glutathione (GSH) plays a critical role in oxidant scavenging. Maintenance of GSH concentrations after SCI lessens secondary injury and improves recovery. Since glutamine promotes GSH synthesis, this nonessential amino acid was examined for therapeutic potential. Denervation alters the expression of myosin heavy chain (MHC) isoforms within skeletal muscles. The hypotheses of this study were that glutamine administration to SCI rats would lead to improved functional recovery and more preserved MHC phenotypes in representative locomotor muscles. Male Wistar rats were divided into four groups: healthy, sham with laminectomy, laminectomized SCI untreated, and laminectomized SCI treated with glutamine. Functional performance was measured weekly for 6 wk using Basso-Beattie-Bresnahan scale and angle board methods. MHC composition of rat soleus and extensor digitorum longus muscles was determined using SDS-PAGE. Glutamine-treated rats had significantly higher angle board scores (P < 0.001) and Basso-Beattie-Bresnahan scores (P < 0.01) than untreated SCI rats. Soleus of healthy rats contained 94% type 1 myosin isoform. Treated rats maintained 68%, which was significantly (P < 0.001) greater than 28% in untreated rats. The extensor digitorum longus of healthy rats contained 55% type 2b myosin. There was a significant (P < 0.001) decrease in this isoform following SCI, but no significant difference between treated and untreated groups. There were strong correlations between higher functional scores and more preserved MHC phenotypes. Our findings suggest glutamine improves functional recovery and helps preserve myosin profile by reducing secondary SCI, thereby maintaining more nerves.
authors.affiliation: Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Rm. A315 Health Science Bldg., 107 Wiggins Road, Saskatoon, Saskatchewan, Canada S7N 5E5.
authors.forename: Jamie D
authors.initials: JD
authors.lastname: Golding
authors.forename: Sarah T
authors.initials: ST
authors.lastname: Rigley MacDonald
authors.forename: Bernhard H J
authors.initials: BH
authors.lastname: Juurlink
authors.forename: Benjamin W C
authors.initials: BW
authors.lastname: Rosser
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005106:Exploratory Behavior / Q000187:drug effects; D005528:Foot; D005973:Glutamine / Q000494:pharmacology*; D007796:Laminectomy; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D018995:Myosin Heavy Chains / Q000378:metabolism*; D020033:Protein Isoforms / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D020033:Protein Isoforms; D005973:Glutamine; D018995:Myosin Heavy Chains